ES2423029T3 - Compuestos de arilsulfonamida - Google Patents

Compuestos de arilsulfonamida Download PDF

Info

Publication number
ES2423029T3
ES2423029T3 ES07864478T ES07864478T ES2423029T3 ES 2423029 T3 ES2423029 T3 ES 2423029T3 ES 07864478 T ES07864478 T ES 07864478T ES 07864478 T ES07864478 T ES 07864478T ES 2423029 T3 ES2423029 T3 ES 2423029T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
rheteroaryl
raryl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07864478T
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Bayldon Baell
Guillaume Laurent Lessene
Brad Edmund Sleebs
Wayne J. Fairbrother
John A. Flygare
Michael F.T. Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research, Genentech Inc filed Critical Walter and Eliza Hall Institute of Medical Research
Application granted granted Critical
Publication of ES2423029T3 publication Critical patent/ES2423029T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES07864478T 2006-11-15 2007-11-15 Compuestos de arilsulfonamida Active ES2423029T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85931506P 2006-11-15 2006-11-15
US859315P 2006-11-15
PCT/US2007/084873 WO2008061208A2 (en) 2006-11-15 2007-11-15 Arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
ES2423029T3 true ES2423029T3 (es) 2013-09-17

Family

ID=39276199

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07864478T Active ES2423029T3 (es) 2006-11-15 2007-11-15 Compuestos de arilsulfonamida

Country Status (9)

Country Link
US (1) US8168645B2 (cg-RX-API-DMAC7.html)
EP (1) EP2094672B1 (cg-RX-API-DMAC7.html)
JP (1) JP5366817B2 (cg-RX-API-DMAC7.html)
CN (1) CN101535280B (cg-RX-API-DMAC7.html)
AU (1) AU2007319209B2 (cg-RX-API-DMAC7.html)
CA (1) CA2666837C (cg-RX-API-DMAC7.html)
ES (1) ES2423029T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ577442A (cg-RX-API-DMAC7.html)
WO (1) WO2008061208A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
CN101983191B (zh) 2008-02-01 2013-11-20 武田药品工业株式会社 作为hsp90抑制剂的肟衍生物
US20110098305A1 (en) * 2008-05-21 2011-04-28 Jonathan Bayldon Baell Arylsulfonamide compounds, compositions and methods of use
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
MX2012003007A (es) * 2009-09-10 2012-04-11 Novartis Ag Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
JP2015502366A (ja) 2011-12-13 2015-01-22 バック インスティテュート フォー リサーチ オン エイジング 薬物療法を改善するための方法
EA201491264A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
CN104125955A (zh) 2011-12-23 2014-10-29 诺华股份有限公司 用于抑制bcl2与结合配偶体相互作用的化合物
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
RU2716256C2 (ru) 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
KR20200108298A (ko) 2018-01-10 2020-09-17 리커리엄 아이피 홀딩스, 엘엘씨 벤즈아미드 화합물
CN108276395B (zh) * 2018-02-09 2021-02-26 合肥华方医药科技有限公司 一种多沙唑嗪杂质的制备方法
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
TW202334089A (zh) 2021-11-02 2023-09-01 美商夫雷爾醫療公司 Ｐｐａｒｇ反向激動劑及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2479362C (en) 2002-03-21 2011-01-04 Abbott Laboratories N-sulfonylurea apoptosis promoters
US7642260B2 (en) * 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
KR101132905B1 (ko) 2003-11-20 2012-04-03 미츠비시 가스 가가쿠 가부시키가이샤 액상 시클로헥산트리카르복실산 무수물
EP1765778B1 (en) * 2004-05-26 2012-01-25 Abbott Laboratories N-sulfonylcarboximidamide apoptosis promoters
BRPI0514504A (pt) * 2004-08-20 2008-06-10 Univ Michigan pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas
US20070072870A2 (en) * 2004-12-08 2007-03-29 Solvay Pharmeceuticals B.V. Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition
CA2606147C (en) * 2005-05-12 2011-07-05 Abbott Laboratories Apoptosis promoters

Also Published As

Publication number Publication date
JP5366817B2 (ja) 2013-12-11
CA2666837C (en) 2015-01-13
NZ577442A (en) 2012-02-24
WO2008061208A3 (en) 2008-07-03
CN101535280A (zh) 2009-09-16
AU2007319209A1 (en) 2008-05-22
US20100056517A1 (en) 2010-03-04
EP2094672B1 (en) 2013-05-29
CA2666837A1 (en) 2008-05-22
CN101535280B (zh) 2012-06-27
WO2008061208A2 (en) 2008-05-22
EP2094672A2 (en) 2009-09-02
US8168645B2 (en) 2012-05-01
JP2010510237A (ja) 2010-04-02
AU2007319209B2 (en) 2012-04-19
HK1134283A1 (en) 2010-04-23

Similar Documents

Publication Publication Date Title
ES2423029T3 (es) Compuestos de arilsulfonamida
ES2967983T3 (es) Compuestos
ES2927182T3 (es) Agentes inductores de la apoptosis
ES2855135T3 (es) Amidas heterocíclicas como inhibidores de quinasa
ES2369652T3 (es) Moduladores c-met y métodos de uso.
ES2360936T3 (es) Indoles sustituidos.
CN108834412B (zh) 嘧啶及其变体、及其用途
ES2802251T3 (es) Compuestos heterocíclicos y métodos para su uso
ES2284007T3 (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
ES2634492T3 (es) Compuestos de quinazolinona
ES2816641T3 (es) Derivados de piperidina en calidad de inhibidores de HDAC1/2
ES2399427T3 (es) Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
ES2379874T3 (es) Compuestos de (2-carboxamido)(3-amino)tiofeno
ES2211851T3 (es) Compuesto de benzoquinozolina farmaceuticamente activos.
PT1944305E (pt) Derivados de quinolina como inibidores de fosfodiesterase
BRPI0613502A2 (pt) derivados bicìclicos como inibidores de p38 cinase
CA2871453A1 (en) Quinazolinedione derivative
CN113924288B (zh) 一种含喹啉基化合物、药物组合物以及其用途
ES2362949T3 (es) Carboxamidas substituidas como antagonistas del receptor metabotrópico de grupo i.
ES2936482T3 (es) Agentes antiinfecciosos
US20210070742A1 (en) Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase
CN103965182A (zh) 制备含1,3,4-噁二唑的吡唑类化合物用于治疗肿瘤的药物
ES2301984T3 (es) Dihidroquinazolinas sustituidas con heterociclilo y su uso como agente antivirico.
ES2328929T3 (es) Dihidroquinazolinas 2-sustituidas.
ES2876285T3 (es) Derivados de acetamida de 2-(1,2,4-triazol-3-ilsulfanil)-N-1,3,4-tiadiazol-2-ilo que son útiles para el tratamiento de la diabetes